Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

has recommended Ebglyss (lebrikizumab) for use in moderate to severe Atopic Dermatitis in the NHS England. On July 9th, 2024, the U.S. FDA approved Arcutis Biotherapeutics' ZORYVE® (roflumilast ...

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of ...

In addition, Thaçi added, the “safety data support the long-term use of nemolizumab for the treatment of adolescent and adult patients with moderate to severe atopic dermatitis.” The current ...

Medscape Medical News, October 01, 2024 EADV 2024 Atopic Dermatitis Control on Biologic Persists Over 3 Years In a 3-year extension of the pivotal trials that provided lebrikizumab with an ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

On Friday, Eli Lilly and Company (NYSE:LLY) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), ...

which showcased the effectiveness of Ebglyss (lebrikizumab) for patients with moderate-to-severe atopic dermatitis who did not respond adequately to Dupixent. The trial results indicated that a ...

Atopic dermatitis (AD) is a highly prevalent chronic ... often negatively affect their day-to-day and long-term well-being. Lebrikizumab, a monoclonal antibody that inhibits an interleukin named ...

On Friday, Eli Lilly and Company (NYSE:LLY) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab ... with moderate-to-severe atopic dermatitis (eczema) who were previously ...

APG777, an extended half-life monoclonal antibody targeting IL-13, a primary driver of AD, has shown equivalent or superior potency in preclinical studies compared to lebrikizumab. The drug's ...